

DIVI'S LABORATORIES LIMITED

UNAUDITED FINANCIAL RESULTS (STANDALONE)
FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2016

PART I

(₹. in Lakhs)

Sl No.	Particulars	STANDALONE (UNAUDITED)				
		Quarter ended			Half Year ended	
		30.09.2016	30.06.2016	30.09.2015	30.09.2016	30.09.2015
	(1)	(2)	(3)	(4)	(5)	(6)
1	Income from operations					
	(a) Sales/Income from operations	100307	101508	96924	201815	178241
	(b) Other Operating Income	236	211	245	447	430
	Total Income from operations	100543	101719	97169	202262	178671
2	Expenses					
	a. Cost of materials consumed	41038	37115	42106	78153	77673
	b. Purchases of stock-in-trade	0	0	0	0	0
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(2564)	1404	(3571)	(1160)	(7084)
	d. Employee benefits expense	16504	9605	8535	26109	16369
	e. Depreciation and amortization expense	3075	3012	3007	6087	5899
	f. Other Expenses	16444	13220	12484	29664	23933
	Total Expenses	74497	64356	62561	138853	116790
3	Profit from Operations before Other Income, finance costs & Exceptional Items (1-2)	26046	37363	34608	63409	61881
4	Other Income	2027	1631	3000	3658	6436
5	Profit from ordinary activities before finance costs & exceptional Items (3+4)	28073	38994	37608	67067	68317
6	Finance Costs	39	38	34	77	56
7	Profit from ordinary activities after finance costs but before exceptional Items (5-6)	28034	38956	37574	66990	68261
8	Exceptional items	0	0	0	0	0
9	Profit from ordinary activities before Tax (7-8)	28034	38956	37574	66990	68261
10	Tax Expense	5649	8775	7884	14424	14053
11	Net Profit from ordinary activities after Tax (9-10)	22385	30181	29690	52566	54208



(Handwritten Signature)



12	Other Comprehensive Income					
	a) Items that will not be reclassified to Profit or Loss	(65)	(65)	(129)	(130)	(259)
	b) Items that will be reclassified to Profit or Loss	0	0	0	0	0
	Total other comprehensive Income	(65)	(65)	(129)	(130)	(259)
13	Total comprehensive Income for the period (11-12)	22320	30116	29561	52436	53949
14	Paid-up Equity Share Capital (Face Value : ₹.2 per share)	5309	5309	5309	5309	5309
15	Earnings per Share (of ₹. 2/- each) (not annualized):					
	a) Basic	8.43	11.37	11.14	19.80	20.32
	b) Diluted	8.43	11.37	11.14	19.80	20.32

Standalone Statement of Assets and Liabilities:

(₹. in lakhs)

	Particulars	As At 30.09.2016
A	ASSETS	
1	Non-current assets	
	a) Property, plant and equipment	147277
	b) Capital work-in-progress	39512
	c) Intangible assets	206
	d) Financial assets	
	i. Investments	1019
	ii. Loans	3396
	iii. Other financial assets	2860
	e) Other non-current assets	12091
	Sub-total – Non-current assets	206361
2	Current assets	
	a) Inventories	116627
	b) Financial assets	
	i. Investments	118730
	ii. Trade receivables	93087
	iii. Cash and cash equivalents	823
	iv. Bank balances other than (iii) above	5650
	v. Other financial assets	402
	c) Other current assets	5461
	Sub-total – Current assets	340780
	TOTAL - ASSETS	547141
B	EQUITY AND LIABILITIES	
1	EQUITY	
	a) Share capital	5309
	b) Other equity	482832
	Sub-total – Equity	488141



(Handwritten signature)



2	Non-current liabilities	
	a) Long Term provisions	1407
	b) Differed Tax liabilities (Net)	8621
	Sub-total – Non-Current liabilities	10028
3	Current Liabilities	
	a) Financial liabilities	
	i. Borrowings	3836
	ii. Trade payables	26869
	iii. Other financial liabilities	15828
	b) Other current liabilities	2222
	c) Short Term provisions	217
	Sub-total – Current liabilities	48972
	TOTAL - EQUITY AND LIABILITIES	547141

NOTES:

1. The above results for the quarter ended 30th September 2016, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 12th November, 2016.
2. Results for the quarter ended 30th September 2016 were subjected to 'limited review' by the Auditors and their report contains no qualification.
3. During the quarter, the company has paid a one-time ex-gratia to employees and whole-time directors of the company aggregating to an amount of Rs.7913 lakhs on the occasion of completion of 25 years' of formation of the company.
4. These results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices to the extent applicable. Effective from 1st April, 2016, the Company has, for the first time, adopted Ind AS with a transition date of 1st April, 2015.
5. The format for un-audited quarterly results as prescribed in SEBI's Circular No.CIR/CFD/CMD/15/2015 dated 30th November, 2015 has been modified to comply with requirements of SEBI's Circular dated 5th July, 2016, Ind AS Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with Ind AS.
6. These results do not include Ind AS compliant results for the previous year ended 31st March, 2016 as the same is not mandatory as per SEBI's circular dated 5th July, 2016.
7. Reconciliation of net profit for the corresponding previous quarter and half-year ended 30.09.2015 in accordance with the Indian GAAP to total comprehensive Income in accordance with Ind AS is given below:

(₹. in lakhs)

Particulars	Quarter ended 30.09.2015	Half-year ended 30.09.2015
Net Profit as per previous GAAP (Indian GAAP)	29573	53891
Ind AS adjustments:		
Effect of measuring non-current investments at fair value through Profit and Loss	(45)	(64)
Actuarial loss on employee defined benefit funds recognised in Other Comprehensive Income	60	259
Others	37	73
Deferred taxes on Ind AS adjustments	65	49
Net Profit as per Ind AS	29690	54208
Other Comprehensive Income	(129)	(259)
Total comprehensive Income for the period	29561	53949



[Handwritten Signature]



8. The Company is engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates and the same constitutes a single reportable business segment as per Ind AS 108.
9. As per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.
10. Pursuant to SEBI Notification No. NSE/CML/2016/12 dated 20.09.2016, net sales reported in the previous periods have been recast to include excise duty.
11. Figures for the previous year/period have been regrouped or recasted, wherever necessary.
12. Details of forex gain/loss and excise duty are given below:

(₹. in lakhs)

	Quarter ended			Half Year ended	
	30.09.2016	30.06.2016	30.09.2015	30.09.2016	30.09.2015
Forex gain/(loss)	(1144)	73	1166	(1071)	3288
Excise duty	1125	911	737	2036	1363

Forex gain has been included in Other Income. Forex loss and Excise duty have been included in Other Expenses.

Place: Hyderabad
Date: 12th November, 2016



for Divi's Laboratories Limited

Dr. Murali K. Divi
Dr. Murali K. Divi
Chairman & Managing Director





INDEPENDENT AUDITOR'S REVIEW REPORT

TO
THE BOARD OF DIRECTORS
DIVI'S LABORATORIES LIMITED

We have reviewed the unaudited financial results of **DIVI'S LABORATORIES LIMITED** ("the Company") for the quarter and half year ended **30th September, 2016** which are included in the accompanying 'Statement of Unaudited Financial Results (Standalone) for the quarter and half year ended 30th September, 2016' and the Statement of assets and liabilities on that date together with the relevant notes thereon ("the Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015"), which has been initialled by us for identification purpose. The Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Further, the Management is also responsible to ensure that the accounting policies used in the preparation of this Statement are consistent with those used in the preparation of Company's opening unaudited Balance Sheet as at April 1, 2015 prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



We draw attention to Note 4 to the statement which states that the Company has adopted Ind AS for the financial year commencing from April 1, 2016, and accordingly, the Statement has been prepared by the Company's Management in compliance with Ind AS.

For P.V.R.K. NAGESWARA RAO & Co.,
Chartered Accountants
Firm's Registration Number: 002283S

HYDERABAD
12.11.2016

N. Anka Rao
N. ANKA RAO
Partner
Membership Number: 23939

